ARS Pharmaceuticals Files 8-K

Ticker: SPRY · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1671858

Ars Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyArs Pharmaceuticals, Inc. (SPRY)
Form Type8-K
Filed DateJun 28, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, corporate-events

TL;DR

ARS Pharma dropped an 8-K on 6/28 detailing events from 6/27 - check it for Reg FD, other events, and financials.

AI Summary

ARS Pharmaceuticals, Inc. filed an 8-K on June 28, 2024, reporting on events that occurred on June 27, 2024. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Silverback Therapeutics, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides updates on significant corporate events and disclosures for ARS Pharmaceuticals, Inc., which could impact investor understanding of the company's current status and future direction.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine corporate events and disclosures, not indicating any immediate financial distress or significant negative news.

Key Players & Entities

  • ARS Pharmaceuticals, Inc. (company) — Registrant
  • Silverback Therapeutics, Inc. (company) — Former company name
  • June 27, 2024 (date) — Date of earliest event reported
  • June 28, 2024 (date) — Date of report
  • San Diego, California (location) — Principal executive offices location

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.

What are the 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.

What financial statements and exhibits are included with this 8-K?

The filing states that 'Financial Statements and Exhibits' are included, but the content of these exhibits is not specified in the provided text.

When was ARS Pharmaceuticals, Inc. formerly known as Silverback Therapeutics, Inc.?

The date of the name change from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. was April 12, 2016.

What is the principal executive office address for ARS Pharmaceuticals, Inc.?

The principal executive offices are located at 11682 El Camino Real, Suite 120, San Diego, California 92130.

Filing Stats: 1,003 words · 4 min read · ~3 pages · Grade level 13.7 · Accepted 2024-06-28 06:46:32

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq

Filing Documents

Forward-Looking Statements

Forward-Looking Statements

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Company Presentation, dated June 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS Pharmaceuticals, Inc. Date: June 28, 2024 By: /s/ Richard Lowenthal Richard Lowenthal, M.S., MSEL President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.